— Know what they know.
Not Investment Advice

NATCOPHARM.BO

NATCO Pharma Limited
1W: +3.2% 1M: +9.3% 3M: +18.5% YTD: +15.2% 1Y: -23.8% 3Y: +84.8% 5Y: +9.8%
₹973.75 ($10.34)
+24.05 (+2.53%)
 
BSE · Healthcare · Drug Manufacturers - Specialty & Generic · ₹174.4B · Alpha Radar Buy · Power 60
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap₹174.4B ($1.9B)
52W Range660.05-1340.45
Volume47,518
Avg Volume113,883
Beta0.12
Dividend₹5.00
Analyst Ratings
No analyst coverage
Company Info
CEORajeev Nannapaneni
Employees4,016
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2001-03-02
NATCO House
Hyderabad 500034
IN
91 40 2354 7532
About NATCO Pharma Limited

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. It markets its products in approximately 50 countries. The company was incorporated in 1981 and is headquartered in Hyderabad, India.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms